Homology Medicines Inc (NASDAQ:FIXX) insider Albert Seymour sold 9,300 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $16.23, for a total transaction of $150,939.00. Following the transaction, the insider now directly owns 172,450 shares of the company’s stock, valued at $2,798,863.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Albert Seymour also recently made the following trade(s):
- On Friday, November 29th, Albert Seymour sold 9,300 shares of Homology Medicines stock. The shares were sold at an average price of $16.06, for a total transaction of $149,358.00.
- On Tuesday, October 1st, Albert Seymour sold 9,300 shares of Homology Medicines stock. The stock was sold at an average price of $17.39, for a total transaction of $161,727.00.
Shares of Homology Medicines stock traded up $1.18 on Tuesday, reaching $18.32. 667,880 shares of the company were exchanged, compared to its average volume of 242,386. The company has a market capitalization of $704.55 million, a price-to-earnings ratio of -9.16 and a beta of 0.14. Homology Medicines Inc has a one year low of $11.05 and a one year high of $31.80. The company has a 50-day moving average of $13.63 and a 200 day moving average of $17.60.
A number of research firms recently weighed in on FIXX. Robert W. Baird assumed coverage on shares of Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 target price for the company. Zacks Investment Research cut shares of Homology Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. HC Wainwright set a $36.00 price objective on shares of Homology Medicines and gave the stock a “buy” rating in a research note on Tuesday, September 24th. ValuEngine cut Homology Medicines from a “buy” rating to a “hold” rating in a report on Monday, November 25th. Finally, Oppenheimer started coverage on Homology Medicines in a report on Friday, November 1st. They issued a “market perform” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Homology Medicines currently has an average rating of “Hold” and a consensus target price of $31.40.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Article: How Short Selling Works
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.